Vistide Side Effects
Generic name: cidofovir
Note: This document contains side effect information about cidofovir. Some of the dosage forms listed on this page may not apply to the brand name Vistide.
Some side effects of Vistide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to cidofovir: intravenous solution
Along with its needed effects, cidofovir (the active ingredient contained in Vistide) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Medicines like cidofovir can sometimes cause serious side effects such as blood problems and kidney problems; these are described below. Cidofovir has also been found to cause cancer in animals, and there is a chance it could cause cancer in humans as well. Discuss these possible side effects with your doctor.
Check with your doctor immediately if any of the following side effects occur while taking cidofovir:More common
- Fever, chills, or sore throat
Check with your doctor as soon as possible if any of the following side effects occur while taking cidofovir:More common
- Decreased urination
- increased thirst and urination
- Decreased vision or any change in vision
Some side effects of cidofovir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- loss of appetite
- Generalized weakness
- loss of strength
For Healthcare Professionals
Applies to cidofovir: intravenous solution
The major side effect associated with cidofovir (the active ingredient contained in Vistide) therapy is renal toxicity. The most common adverse effects reported in clinical trials were proteinuria (50%), neutropenia (24%), decreased intraocular pressure (24%), decreased serum bicarbonate levels (16%), fever (14%), infection (12%), increased serum creatinine levels >= 2 mg/dL (12%), pneumonia (9%), dyspnea (8%), and nausea/vomiting (7%). The drug was discontinued in 39% of patients because of various adverse effects.
Renal side effects have included nephrotoxicity. It may be irreversible and is the major side effect associated with cidofovir (the active ingredient contained in Vistide) therapy. Renal impairment, including cases of acute renal failure resulting in dialysis and/or contributing to death, has occurred with as few as one or two doses of the drug. Proteinuria (greater than 2+), reduced creatinine clearance (less than or equal to 55 mL/min), and/or elevations of serum creatinine concentration (greater than 0.4 mg/dL) occurred in about 59% of patients receiving a maintenance dose of 5 mg/kg every other week. Toxic nephropathy has also been reported.
Adequate hydration and concomitant administration of probenecid is essential to lessen the risk of renal toxicity associated with cidofovir. Proteinuria, as measured by urinalysis, may be an early indicator of cidofovir-associated nephrotoxicity. Serum creatinine concentrations and routine urinalysis should be monitored prior to each dose of cidofovir. In patients with proteinuria, intravenous hydration should be administered and the urinalysis repeated. Patients who have had previous therapy with foscarnet may be at increased risk of renal toxicity and should be monitored closely.
The risk of ocular hypotony may be increased in patients with diabetes mellitus.
Uveitis or iritis was reported in 15 (11%) of 135 patients who were administered the 5 mg/kg maintenance dose. Patients should be monitored for signs and symptoms of these complications and if they develop, treatment with topical corticosteroids with or without topical cycloplegic agents may be useful.
Ocular side effects have included decreases intraocular pressure by more than 50% from baseline in 24% of patients in clinical trials; severe ocular hypotony (IOP less than 0.1 mmHg) occurred in 4%. Abnormal vision, amblyopia, blindness, cataract, conjunctivitis, corneal lesion, corneal opacity, diplopia, dry eyes, eye disorder, eye pain, iritis, keratitis, miosis, retinal detachment, retinal disorder, uveitis, and visual field defect have also been reported.
Metabolic side effects including a decreased serum bicarbonate level to less than or equal to 16 mEq/L (16%) and multiple abnormalities of proximal renal tubular function or Fanconi's syndrome (1%) have occurred. Cases of metabolic acidosis, in association with liver dysfunction and pancreatitis, which resulted in death have also been reported. Cachexia, dehydration, edema, hypercalcemia, hyperglycemia, hyperkalemia, hyperlipemia, hypocalcemia, hypoglycemia, hypoglycemic reaction, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypoproteinemia, increased alkaline phosphatase, increased BUN, increased lactic dehydrogenase, increased SGOT, increased SGPT, peripheral edema, respiratory alkalosis, thirst, weight loss, and weight gain have also been observed in clinical trials. However, it could not be definitively determined from these trials that cidofovir (the active ingredient contained in Vistide) was the causative agent.
Genitourinary side effects have included dysuria, glycosuria, hematuria, kidney stone, mastitis, metrorrhagia, nocturia, polyuria, prostatic disorder, urethritis, urinary casts, urinary incontinence, urinary retention, and urinary tract infection, although a causal relationship to cidofovir (the active ingredient contained in Vistide) was difficult to determine.
Hematologic side effects have included neutropenia, anemia, and thrombocytopenia. Hypochromic anemia, leukocytosis, leukopenia, lymphadenopathy, lymphoma-like reaction, pancytopenia, splenic disorder, splenomegaly, thrombocytopenia, and thrombocytopenic purpura have also been reported but a causal relationship to cidofovir (the active ingredient contained in Vistide) was difficult to determine.
Neutropenia (less than 500 cells/mm3) occurred in 24% of patients receiving cidofovir for CMV retinitis in clinical trials. Granulocyte colony-stimulating factor was used in 39% of patients to manage neutropenia due to cidofovir.
Hypersensitivity or allergic reactions may include rash, fever, chills, and anaphylaxis. Patients receiving concomitant probenecid and cidofovir (the active ingredient contained in Vistide) may experience hypersensitivity reactions caused by probenecid. Cidofovir and probenecid therapy should be discontinued in patients who experience severe systemic reactions.
Two patients developed erythroderma associated with concomitant administration of cidofovir and probenecid. Prophylactic or therapeutic use of antihistamines and/or acetaminophen may alleviate hypersensitivity reactions associated with the use of probenecid.
Administration of probenecid after a meal and/or therapy with antiemetics may alleviate the nausea and vomiting associated with probenecid.
Gastrointestinal side effects such as nausea and/or vomiting have occurred in 69% of patients receiving concomitant probenecid and cidofovir for CMV retinitis. Diarrhea (26%), anorexia (23%), and abdominal pain (17%) also have been reported. Cholangitis, colitis, constipation, dysphagia, dyspepsia, esophagitis, fecal incontinence, flatulence, gastritis, gastrointestinal hemorrhage, gingivitis, melena, pancreatitis, proctitis, rectal disorder, stomatitis, aphthous stomatitis, tongue discoloration, mouth ulceration, and tooth caries have also been reported; however, a causal relationship to cidofovir was difficult to determine.
Cardiovascular side effects such as cardiomyopathy, cardiovascular disorder, congestive heart failure, hypertension, hypotension, migraine, pallor, peripheral vascular disorder, postural hypotension, shock, syncope, tachycardia, vascular disorder, and edema have been reported from clinical trials. It was difficult, however, to prove a causal relationship to cidofovir (the active ingredient contained in Vistide) because many of the studied patients had very advanced disease and were administered numerous concomitant medications.
Dermatological side effects which included rash (30%) and alopecia (27%) were observed in clinical trials that included the use of probenecid. Acne, angioedema, dry skin, eczema, exfoliative dermatitis, furunculosis, herpes simplex, nail disorder, pruritus, seborrhea, skin discoloration, skin disorder, skin hypertrophy, skin ulcer, sweating, and urticaria have also been reported in clinical trials. It is important to note that these trials included patients with very advanced disease who were also taking numerous concomitant medications, therefore, a causal relationship to cidofovir (the active ingredient contained in Vistide) was difficult to determine.
Phlebitis has been reported with the use of intravenous cidofovir (the active ingredient contained in Vistide)
Endocrine adverse effects are not common. Adrenal cortex insufficiency has been reported, although, a direct causal relationship to cidofovir (the active ingredient contained in Vistide) was not determined.
Hepatic adverse effects are not common. Hepatitis, hepatomegaly, hepatosplenomegaly, jaundice, abnormal liver function, liver damage, and liver necrosis were reported in clinical trials although a causal relationship to cidofovir (the active ingredient contained in Vistide) was difficult to determine due to the fact that most of the patients received many concomitant medications and due to the broad manifestations of the underlying disease.
Musculoskeletal side effects which have been reported in clinical trials regardless of the relationship to cidofovir (the active ingredient contained in Vistide) or probenecid include arthralgia, asthenia, arthrosis, bone necrosis, bone pain, joint disorder, leg cramps, myalgia, myasthenia, back pain, neck pain, and pathological fracture.
Nervous system side effects have included abnormal dreams, abnormal gait, acute brain syndrome, agitation, amnesia, anxiety, ataxia, cerebrovascular disorder, confusion, convulsion, delirium, dementia, depression, dizziness, drug dependence, dry mouth, encephalopathy, facial paralysis, hallucinations, headache, hemiplegia, hyperesthesia, hypertonia, hypotony, incoordination, increased libido, insomnia, myoclonus, nervousness, neuropathy, paresthesia, personality disorder, somnolence, speech disorder, tremor, twitching, vasodilatation, and vertigo. A definitive causal relationship to cidofovir (the active ingredient contained in Vistide) was difficult to make, however, from these trials.
Oncologic side effects have not been observed in humans. In a 26-week animal study, however, cidofovir (the active ingredient contained in Vistide) was found to be carcinogenic in rats.
Respiratory side effects such as asthma, bronchitis, dyspnea, epistaxis, hemoptysis, hiccup, hyperventilation, hypoxia, increased sputum, larynx edema, lung disorder, pharyngitis, pneumonia, pneumothorax, rhinitis, sinusitis, and increased cough have been reported in clinical trials, however, a causal relationship to cidofovir (the active ingredient contained in Vistide) was difficult to determine.
Other side effects reported in clinical trials regardless of the relationship to cidofovir (the active ingredient contained in Vistide) or probenecid were flu-like syndrome, hypothermia, malaise, mucous membrane disorder, photosensitivity reaction, sarcoma, infection, sepsis, oral moniliasis, taste perversion, ear disorder, ear pain, hyperacusis, otitis externa, otitis media, tinnitus, and hearing loss.
More Vistide resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.